By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11 rue de MOLSHEIM, 67082
Cedex      France
Phone: 011-33-3-88-27-91-21 Fax: 011-33-3-88-27-91-11



Gene Therapy


Human Genome Sciences, Inc.  Gene Therapy Partnerships

Company News
TRANSGENE (ENX:TNG) Announces Management Changes 10/9/2014 10:58:35 AM
TRANSGENE (ENX:TNG) Presents Additional Positive Clinical Data From Phase 2b Part Of TIME Trial With TG4010 At ESMO 9/29/2014 9:52:48 AM
TRANSGENE (ENX:TNG) Appoints Eric Quéméneur, PhD As Executive Vice President In Charge Of Research & Development 9/23/2014 11:50:10 AM
TRANSGENE (ENX:TNG) Reports Financial Results For First Six Months Of 2014 And Provides Update On TG4010 9/9/2014 11:18:42 AM
TRANSGENE (ENX:TNG)-Tasly Pharmaceutical JV Reports Immunotherapy Progress 7/2/2014 11:52:19 AM
TRANSGENE (ENX:TNG) Announces Presentation Of Data On TG1050 Immunotherapy Against Chronic Hepatitis B And Provides Update On Its Joint Venture With Tasly Pharmaceutical In China 7/1/2014 10:46:07 AM
TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer 5/27/2014 10:40:15 AM
TRANSGENE (ENX:TNG) Reports Progress With Its Proprietary Oncolytic Immunotherapy To Treat Solid Tumors 5/15/2014 12:06:49 PM
TRANSGENE (ENX:TNG) Announces Presentations At Upcoming Investor Conferences 5/12/2014 9:59:59 AM
TRANSGENE (ENX:TNG) Drops As Novartis AG (NVS) Decides To Pass On Bypass Drug; Stock Down -17.98% At Market Close (April 29, 2014) 4/29/2014 8:13:22 AM